Skip to main content
PMC home page
Clinical Cardiology logoLink to Clinical Cardiology
. 2010 Apr 30;33(6):E40–E48. doi: 10.1002/clc.20730

The Causes and Outcomes of Inadequate Implementation of Existing Guidelines for Antiplatelet Treatment in Patients With Acute Coronary Syndrome: The Experience From Taiwan Acute Coronary Syndrome Descriptive Registry (T‐ACCORD Registry)

Cheng‐I Cheng 1,2, Ching‐Pei Chen 3, Pei‐Liang Kuan 4, Meng‐Huan Lei 5, Chiau‐Suong Liau 6, Kwo‐Chang Ueng 7, Chiung‐Jen Wu 1,2, Wen‐Ter Lai 8,✉
PMCID: PMC6653408  PMID: 20552592

Abstract

Background

Benefits of antiplatelet agents in preventing future cardiovascular events have been well established. However, the prescription pattern of antiplatelet usage in patients with acute coronary syndrome (ACS) is rarely investigated. Hence, Taiwan ACute CORonary Syndrome Descriptive Registry (T‐ACCORD Registry) aimed to evaluate medical practices in Taiwan in managing ACS patients.

Hypothesis

The guidelines of antiplatelet treatment is not properly implanted in the management of ACS patients.

Methods

This prospective observational study was performed between April 2004 and December 2006 in 27 hospitals in Taiwan. A total of 1331 patients with unstable angina or non–ST‐elevation myocardial infarction (NSTEMI) discharged from hospitals was analyzed.

Results

The patients with older age, lower hemoglobin levels, or previous cardiovascular ischemic diseases were less likely to receive aspirin at discharge, whereas patients with NSTEMI were less likely to receive clopidogrel at discharge. The prescription of dual antiplatelet agents declined rapidly from 61.8% at discharge to 12.6% at 12 months. The most common reason for clopidogrel discontinuation was recorded as physician's judgment. Dual antiplatelet treatment for 9 months or longer was associated with lower 1‐year mortality. Percutaneous coronary intervention (PCI) was the only factor leading to dual antiplatelet therapy for at least 9 months.

Conclusions

Our registry showed that underlying medical conditions may affect antiplatelet prescriptions at discharge. During the first year following an ACS episode, the prescription rate of dual antiplatelet therapy declined over time, mainly due to physician's judgment leading to the discontinuation of clopidogrel. Adherence to dual antiplatelet treatment was associated with lower total mortality at 1 year. Copyright © 2010 Wiley Periodicals, Inc.

Full Text

The Full Text of this article is available as a PDF (674.3 KB).

References

  • 1. O'Kelly BF, Massie BM, Tubau JF, et al. Coronary morbidity and mortality, pre‐existing silent coronary artery disease, and mild hypertension. Ann Intern Med 1989; 110: 1017–1026. [DOI] [PubMed] [Google Scholar]
  • 2. Bakhai A. The burden of coronary, cerebrovascular and peripheral arterial disease. Pharmacoeconomics 2004; 22(suppl 4): 11–18. [DOI] [PubMed] [Google Scholar]
  • 3. Leal J, Luengo‐Fernández R, Gray A, et al. Economic burden of cardiovascular diseases in the enlarged European Union. Eur Heart J 2006; 27: 1610–1619. [DOI] [PubMed] [Google Scholar]
  • 4. Wang G, Zheng ZJ, Heath G, et al. Economic burden of cardiovascular disease associated with excess body weight in U.S. adults. Am J Prev Med 2002; 23: 1–6. [DOI] [PubMed] [Google Scholar]
  • 5. DeMartini TJ, Loeb HS. Coronary artery disease and the acute coronary syndrome. Ann Intern Med 2003; 139: W82. [DOI] [PubMed] [Google Scholar]
  • 6. Ault KA, Cannon CP, Mitchell J, et al. Platelet activation in patients after an acute coronary syndrome: results from the TIMI‐12 trial. Thrombolysis in Myocardial Infarction. J Am Coll Cardiol 1999; 33: 634–639. [DOI] [PubMed] [Google Scholar]
  • 7. Massberg S, Schulz C, Gawaz M. Role of platelets in the pathophysiology of acute coronary syndrome. Semin Vasc Med 2003; 3: 147–162. [DOI] [PubMed] [Google Scholar]
  • 8. Song SW, Youn YN, Yi G, et al. Effects of continuous administration of clopidogrel before off‐pump coronary artery bypass grafting in patients with acute coronary syndrome. Circ J 2008; 72: 626–632. [DOI] [PubMed] [Google Scholar]
  • 9. Bhatt DL, Topol EJ. Clopidogrel added to aspirin versus aspirin alone in secondary prevention and high‐risk primary prevention: rationale and design of the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. Am Heart J 2004; 148: 263–268. [DOI] [PubMed] [Google Scholar]
  • 10. Hennekens CH, Buring JE, Sandercock P, et al. Aspirin and other antiplatelet agents in the secondary and primary prevention of cardiovascular disease. Circulation 1989; 80: 749–756. [DOI] [PubMed] [Google Scholar]
  • 11. Wu TG, Zhao Q, Huang WG, et al. Effect of intracoronary tirofiban in patients undergoing percutaneous coronary intervention for acute coronary syndrome. Circ J 2008; 72: 1605–1609. [DOI] [PubMed] [Google Scholar]
  • 12. Braunwald E, Antman EM, Beasley JW, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST‐segment elevation myocardial infarction—summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Guidelines for the Management of Patients With Unstable Angina and Non–ST‐segment Myocardial Infarction). J Am Coll Cardiol 2002; 40: 1366–74. [DOI] [PubMed] [Google Scholar]
  • 13. Bassand JP, Hamm CW, Ardissino D, et al. Guidelines for the diagnosis and treatment of non–ST‐segment elevation acute coronary syndromes. Eur Heart J 2007; 28: 1598–1660. [DOI] [PubMed] [Google Scholar]
  • 14. Roe MT, Peterson ED, Newby LK, et al. The influence of risk status on guideline adherence for patients with non–ST‐segment elevation acute coronary syndromes. Am Heart J 2006; 151: 1205–1213. [DOI] [PubMed] [Google Scholar]
  • 15. Budaj A, Brieger D, Steg PG, et al. Global patterns of use of antithrombotic and antiplatelet therapies in patients with acute coronary syndromes: insights from the Global Registry of Acute Coronary Events (GRACE). Am Heart J 2003; 146: 999–1006. [DOI] [PubMed] [Google Scholar]
  • 16. Brieger D, Eagle KA, Goodman SG, et al. Acute coronary syndromes without chest pain, an underdiagnosed and undertreated high‐risk group: insights from the Global Registry of Acute Coronary Events. Chest 2004; 126: 461–469. [DOI] [PubMed] [Google Scholar]
  • 17. Bottorff MB, Nutescu EA, Spinler S. Antiplatelet therapy in patients with unstable angina and non–ST‐segment elevation myocardial infarction: findings from the CRUSADE national quality improvement initiative. Pharmacotherapy 2007; 27: 1145–1162. [DOI] [PubMed] [Google Scholar]
  • 18. Steg PG, López‐Sendón J, Lopez de Sa E, et al. External validity of clinical trials in acute myocardial infarction. Arch Intern Med 2007; 167: 68–73. [DOI] [PubMed] [Google Scholar]
  • 19. Yusuf S, Zhao F, Mehta SR, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST‐segment elevation. N Engl J Med 2001; 345: 494–502. [DOI] [PubMed] [Google Scholar]
  • 20. Scirica BM, Sabatine MS, Morrow DA, et al. The role of clopidogrel in early and sustained arterial patency after fibrinolysis for ST‐segment elevation myocardial infarction: the ECG CLARITY‐TIMI 28 Study. J Am Coll Cardiol 2006; 48: 37–42. [DOI] [PubMed] [Google Scholar]
  • 21. Chen ZM, Jiang LX, Chen YP, et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo‐controlled trial. Lancet 2005; 366: 1607–1621. [DOI] [PubMed] [Google Scholar]
  • 22. Steinhubl SR, Berger PB, Mann JT III, et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411–2420. [DOI] [PubMed] [Google Scholar]
  • 23. Bernardi V, Szarfer J, Summay G, et al. Long‐term versus short‐term clopidogrel therapy in patients undergoing coronary stenting (from the Randomized Argentine Clopidogrel Stent [RACS] trial). Am J Cardiol 2007; 99: 349–352. [DOI] [PubMed] [Google Scholar]
  • 24. Eisenstein EL, Anstrom KJ, Kong DF, et al. Clopidogrel use and long‐term clinical outcomes after drug‐eluting stent implantation. JAMA 2007; 297: 159–168. [DOI] [PubMed] [Google Scholar]
  • 25. Anderson JL, Adams CD, Antman EM, et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non–ST‐elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines for the Management of Patients With Unstable Angina/Non–ST‐elevation Myocardial Infarction) developed in collaboration with the American College of Emergency Physicians, the Society for Cardiovascular Angiography and Interventions, and the Society of Thoracic Surgeons endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the Society for Academic Emergency Medicine [published correction appears in J Am Coll Cardiol. 2008;51:974). J Am Coll Cardiol 2007; 50: e1–e157. [DOI] [PubMed] [Google Scholar]

Articles from Clinical Cardiology are provided here courtesy of Wiley

RESOURCES